

October 4, 2016

Press release

Teikoku Seiyaku Co., Ltd.  
Mitsubishi Tanabe Pharma Corporation

## **Execution of Basic Agreement for Sales Anti-Allergy Agent, Rupatadine Tablets**

Teikoku Seiyaku Co., Ltd. (Head Office: Higashikagawa City, Kagawa; President and CEO: Misako Fujioka) and Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka City; President and Representative Director: Masayuki Mitsuka) have reached a basic agreement for sales of Rupatadine tablets (generic name: rupatadine fumarate) in Japan.

Rupatadine tablets are an oral anti-allergy agent developed by J. Uriach Y COMPANIA, S.A., in Spain. The drug is marketed in more than 60 countries around the world, mainly in Europe, principally under the brand name Rupafin<sup>®</sup>. Overseas, it has indications of allergic rhinitis and urticaria and is administered orally at a dosage of 10mg once a day.

In Japan, Teikoku Seiyaku is developing Rupatadine and plans to file an application for manufacturing and marketing approval shortly. After the approval is granted, Teikoku Seiyaku will supply finished products to Mitsubishi Tanabe Pharma and Mitsubishi Tanabe Pharma will distribute and sell the products to the market. Medicinal drug promotion will be conducted jointly by both companies.

In addition, the two companies have reached an agreement regarding co-promotion activities for Talion<sup>®</sup> tablets. According to the agreement, Teikoku Seiyaku is going to start co-promotion of Talion<sup>®</sup> tablets from January 1, 2017. Through these activities, Teikoku Seiyaku and Mitsubishi Tanabe Pharma aim to implement the medicinal drug promotion more promptly after the launch of Rupatadine tablets and to propose two treatment options — Rupatadine tablets and Talion<sup>®</sup> tablets — to patients in accordance with their symptoms and lifestyles.

Kiyoshi Ohta, Executive Director, Sales & Marketing Department at Teikoku Seiyaku, said “Teikoku Seiyaku has been working to broadly address the needs of patients by developing drugs from the patient’s viewpoint and providing the drugs to the market in collaboration with sales partners that specialize in the therapeutic areas of those drugs. We believe the agreements will enable us to deliver Rupatadine tablets, the newest anti-allergy agent in Japan, to more patients through close cooperative relationship with Mitsubishi Tanabe Pharma, which has a strong presence in the field of allergic disorders.

Yoshiaki Ishizaki, Director, Managing Executive Officer, and Division Manager of Sales & Marketing Division for Mitsubishi Tanabe Pharma, said “As with the priority disease areas under our Medium-Term Management Plan, we will continue to advance strategic sales and marketing activities in the field of allergic disorders. Under this agreement, Mitsubishi Tanabe Pharma and Teikoku Seiyaku will work together to provide information regarding Talion<sup>®</sup> to a larger number of medical institutions. Furthermore, following the acquisition of manufacturing and marketing approval for Rupatadine tablets, we will be able to offer a new treatment option. Through these two drugs, we will be able to make a further contribution to the treatment of allergic disorders.”

**About Teikoku Seiyaku**

Teikoku Seiyaku is a privately-owned specialty pharmaceutical company headquartered in Kagawa, Japan. Based on the years of experience in development of anti-inflammatory/analgesic patch technology, Teikoku has been specializing in “analgesic” and “transdermal” medications. In 2014, Teikoku established its own sales force and began marketing not only patch products, but oral and topical drugs to address the patient’s needs in the field of dermatology and pain. Teikoku’s goal is to improve the quality of life of people through developing and providing novel and unique drugs in the fields.

**About Mitsubishi Tanabe Pharma Corporation**

Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical company with a Head Office based in Dosho-machi Osaka, the birthplace of Japan’s pharmaceutical industry. As part of its “Medium-Term Management Plan 16-20: Open Up the Future,” the company is focused on discovering drugs that address unmet medical needs in several priority disease areas, including central nervous system diseases, autoimmune disorders, diabetes, kidney disease and vaccines. Through this work, the company contributes to the healthier lives of people around the world. For more information, go to [www.mt-pharma.co.jp/e](http://www.mt-pharma.co.jp/e).

For further information, please contact:	
Mitsubishi Tanabe Pharma Corporation Corporate Communications Department TEL : +81-6-6205-5211	Teikoku Seiyaku Co., Ltd. General Affairs Department TEL : +81-879 -25-2221